CeriBell (NASDAQ:CBLL) Given “Buy” Rating at Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of CeriBell (NASDAQ:CBLL) in a report issued on Wednesday,Benzinga reports. The firm currently has a $33.00 price objective on the stock.

A number of other equities analysts also recently weighed in on CBLL. Canaccord Genuity Group assumed coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective on the stock. Bank of America initiated coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price for the company. TD Cowen lifted their target price on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, William Blair initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell presently has a consensus rating of “Buy” and a consensus target price of $32.60.

CeriBell Trading Down 1.3 %

Shares of NASDAQ:CBLL opened at $25.20 on Wednesday. The company’s fifty day moving average is $23.40. CeriBell has a 1-year low of $18.69 and a 1-year high of $32.75.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. As a group, sell-side analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

Institutional Trading of CeriBell

Hedge funds have recently made changes to their positions in the company. FMR LLC bought a new position in shares of CeriBell during the 4th quarter worth $128,120,000. Corebridge Financial Inc. bought a new position in CeriBell during the fourth quarter worth about $158,000. Board of Trustees of The Leland Stanford Junior University purchased a new position in shares of CeriBell in the fourth quarter worth about $16,143,000. Norges Bank bought a new stake in shares of CeriBell in the fourth quarter valued at approximately $422,000. Finally, Next Century Growth Investors LLC bought a new stake in shares of CeriBell in the fourth quarter valued at approximately $5,299,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.